Latest filing published 29 May 2026 for Exelixis, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Stelios Papadopoulos (board member) discloses dealings in 4 companies, chiefly Exelixis, Inc., Regulus Therapeutics Inc. and Biogen Inc. Between 4 January 2016 and 27 May 2026, the trades on record add up to 20 filings.
Every open-market trade on record is a sale: 2 sales worth €5.2M. Other entries cover 14 share grants and 3 option exercises.
On 29 May 2026 came the latest disclosure, a share grant in Exelixis, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations